Engflag

Adaptol-Aversi

Quick links to important sections

Adaptol-Aversi

Adaptol-Aversi_EN

Method of action: Antioxidant, Anxiolytic, Membrane Stabilizing, Nootropic, Tranquilizing

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Adaptol-Aversi

Property Description
Active ingredient Mebicarum (Temgicoluril)
Form Oral Solid Dosage (Tablets)
Pharmacological Class Anxiolytic Agent / Nootropic
General Purpose Reduction of emotional tension and irritability
Origin Synthetic compound (Biureas group), manufactured by Aversi-Rational (Georgia)
Status Group II Prescription Medication

What Type of Drug is Adaptol-Aversi?

Adaptol-Aversi is a prescription medication whose active compound is Mebicarum, officially designated by the International Nonproprietary Name (INN) as Temgicoluril. This synthetic molecule is categorized primarily as an Anxiolytic Agent, a class of drugs used to alleviate states of tension and anxiety. It is classified under Other Psychostimulants and Nootropics, reflecting its dual role in promoting emotional stability while potentially supporting cognitive functions. The medicine is manufactured by Aversi-Rational in Georgia and is designated as a Group II prescription medication.

As a single active ingredient product, Adaptol-Aversi is prepared for patient use as an oral solid dosage form in the form of tablets. The compound is chemically derived from the Biureas group, giving it a chemical structure distinct from many conventional anxiolytics, such as those in the benzodiazepine class.

How Does Adaptol-Aversi Generally Benefit Emotional Tension?

The core general purpose of Adaptol-Aversi is to help reduce feelings of internal emotional tension, anxiety symptoms, and irritability by providing a stress-protective effect on the nervous system. The drug's action is recognized for modulating emotional centers within the limbic-reticular region, achieving emotional stabilization without causing significant suppression of overall central nervous system activity.

This pharmacological action results in a characteristic known as a non-sedating tranquilizing effect. The compound is designed to reduce anxiety symptoms and autonomic dysfunction while demonstrating an improvement in cognitive functions. This means the drug is intended to provide emotional balance without generally impairing the user's motor function or capacity for concentration, allowing for its potential use in scenarios such as managing anxiety related to nicotine withdrawal.

What side effects are possible with Adaptol-Aversi?

Possible Side Effects and Safety Information

The safety profile of Adaptol-Aversi (Mebicarum/Temgicoluril) describes potential adverse effects based on official government regulatory documents. The information is grouped by the frequency of occurrence and the physiological system involved, adhering strictly to official regulatory classifications.

Official Adverse Reaction Classifications

Adverse effects are primarily classified as Rare or associated with the initiation of therapy. Regulatory sources list reactions across several System-Organ Classes (SOC):

  • Immune System Disorders and Gastrointestinal Disorders contain effects categorized as Rare, including allergic reactions (such as skin rash and itching) and dyspeptic phenomena (indigestion or discomfort).
  • Vascular Disorders and General Disorders relate to reported physiological changes, such as a temporary lowering of blood pressure and lowering of body temperature.

Safety Constraints and Time-Related Patterns

Official labeling documents that the physiological changes observed (reduced blood pressure and temperature) are generally transient and may occur specifically at the beginning of treatment. These changes are typically temporary and often resolve without intervention.

Serious Adverse Reactions linked to the medicine involve severe manifestations of allergic reactions, most notably angioedema (swelling of the face, lips, or throat), which is considered a condition requiring immediate attention.

Regulatory Restriction

The primary safety constraint documented in official labeling is a contraindication against using Adaptol-Aversi in individuals with known individual hypersensitivity (allergy) to Mebicarum or any other components of the tablet formulation.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Adaptol-Aversi (Mebicarum) is characterized by a low documented risk of severe overexposure, focusing on a specific set of non-severe, transient clinical signs.

Documented Overdose Manifestations

Regulatory documents confirm that manifestations following the administration of high doses are typically not severe and are completely reversible. The officially documented presentations of overexposure include:

  • Transient low blood pressure (Hypotension)
  • Transient low body temperature (Hypothermia)
  • Allergic reactions, such as skin itching
  • General systemic effects, including weakness, dizziness, and dyspeptic symptoms

Crucially, official data explicitly states that no severe adverse reactions or life-threatening outcomes have been reported in clinical practice with Mebicarum. The documented effects are considered transient, and medical assessment is required until they normalize.

Regulatory-Mandated Emergency Actions

The primary instruction regarding overexposure is a direct, required action:

Seek immediate consultation with a doctor.

This instruction applies when a patient has taken more than the prescribed amount. Management of the documented symptoms is supportive, as the low blood pressure and low body temperature effects typically resolve spontaneously after the medicine is discontinued. No specific antidote is known or documented in the official prescribing information for Mebicarum. Urgent professional medical assessment is required following overexposure to ensure proper observation.

Therapeutic Uses of Adaptol-Aversi

What Adaptol-Aversi Treats: Main Uses and Benefits

Adaptol-Aversi is applied across therapeutic domains where additional symptomatic support is needed to manage emotional and somatic tension. It is commonly used for conditions characterized by heightened emotional stress, including various neurotic disorders and anxiety disorders, as well as somatoform disorders of the vegetative nervous system (autonomic dysfunction).

The medication is applied in addressing symptom clusters that may become intense or disruptive, such as chronic inner tension, irritability, fear, and symptoms related to physical discomfort like non-cardiac chest discomfort (cardialgias) and stress-related palpitations. It plays a role in managing distress during nicotine abstinence and supports symptom management when using complex psychotropic regimens. The profile of Adaptol-Aversi is considered relevant in clinical settings where symptoms interfere with daily functioning, as it assists with maintaining functional stability and cognitive functions.

Quick Fact: Relief for Non-Sedating Anxiety

It helps address symptom clusters that interfere with daily functioning and contributes to improved comfort during periods of heightened symptoms.

Eligibility and Restrictions for Use

Eligibility for Adaptol-Aversi (Mebicarum) Use

Official regulatory documentation defines eligibility for Adaptol-Aversi (Mebicarum) based on age, physiological status, and known hypersensitivity to the drug. These restrictions govern who is allowed to use the medicine and who must be excluded.

Populations for Whom Use is Contraindicated or Not Recommended

The medicine is formally contraindicated for patients with a known hypersensitivity or allergy to Mebicarum (Temgicoluril) or any of the product’s excipients.

Population Group Regulatory Status
Pediatrics (under 18) Not recommended; safety and efficacy are not established.
Pregnancy Not recommended due to insufficient safety data.
Breastfeeding Not recommended due to insufficient safety data.
Renal Impairment Use with caution; dose adjustment has not been studied.

Established and Conditional Use

Use of Adaptol-Aversi is established for adults (18 years and older). For older adults, dose adjustment is typically not specified as necessary. For patients with liver failure, no dose reduction is required according to the official prescribing information, although caution is warranted for all patients with organ dysfunction.

What should I know about interactions with other medicines?

Adaptol-Aversi (Mebicar) is generally considered to have a favorable interaction profile compared to some other tranquilizers. Clinical data suggest that Mebicar does not have a reported interaction with the cytochrome P450 enzyme system, which is responsible for metabolizing many medications. This minimal impact on drug metabolism pathways is one reason for its low potential for pharmacokinetic interactions.

Potential for Additive Effects

While Adaptol-Aversi's active ingredient is structurally distinct from traditional benzodiazepines, it still possesses anxiolytic activity. Therefore, the most significant interactions involve other substances that depress the central nervous system (CNS). Concurrent use with the following agents may result in increased sedation, drowsiness, or impaired coordination:

  • Sedatives and Hypnotics: Including benzodiazepines (e.g., diazepam, lorazepam), barbiturates, and non-benzodiazepine hypnotics.
  • Antidepressants and Antipsychotics: Specifically those with known sedative properties.
  • Opioid Pain Relievers: Such as morphine or codeine.
  • Alcohol: Consumption of alcoholic beverages must be strictly avoided while taking Adaptol-Aversi, as alcohol significantly enhances the CNS depressant effects of the drug.

Patients should always inform their healthcare provider of all prescription drugs, over-the-counter medications, and herbal supplements being taken to ensure safe co-administration.

Mechanism of Action

How Adaptol-Aversi Works

Adaptol-Aversi (Temgicoluril) exerts its mechanism through multi-pathway engagement within the central nervous system, targeting key regulatory systems.

Modulation of Key Neurotransmitter Systems

The compound modulates the activity of four core neurotransmitter systems: GABA, choline, serotonin, and adrenergic pathways. It specifically influences catecholamine metabolism, resulting in a reduction of brain norepinephrine levels while promoting an increase in serotonin levels. This dual action alters the balance of neurotransmitter activity within the central nervous system.

Regulation of the Limbic-Reticular System

Adaptol-Aversi primarily acts upon the limbic-reticular structure by targeting the hypothalamic emotional centers. This modulation of key brain regions involved in arousal and emotional processing influences the subsequent physiological and behavioral outputs mediated by these interconnected systems.

Enhancement of Systemic Integration

Beyond specific receptor affinity, the drug engages mechanisms that influence endogenous, nonspecific systems of integration and regulation. This cascade modifies early molecular steps that shape overall systemic physiological outcomes, altering the threshold of response within regulatory systems and influencing internal feedback mechanisms.

Dosage and Administration Information

Official Administration Guidelines for Adaptol-Aversi

Adaptol-Aversi (Mebicarum) is administered via the oral route as a solid dosage form (tablets or capsules) and is designed for use in defined, time-bound courses of treatment. Dosing and administration follow established guidelines.

Standard Adult Dosing and Frequency

The typical adult regimen is based on a divided daily dose, usually taken two to three times per day. The standard daily amount ranges from 600 mg to 1,500 mg. For instances such as supportive use during nicotine abstinence, a total daily intake of 600 mg to 1,000 mg is specified. The maximum single dose is 3,000 mg (3 g) and the absolute maximum daily dose is 10,000 mg (10 g).

Administration Context and Duration

The medicine can be taken independently of food intake, allowing for flexible scheduling. General treatment courses typically range from a few days up to two to three months. Specific support for nicotine abstinence is defined as a specialized course of five to six weeks.

Population-Specific Rules

Patient Group Official Administration Rule
Pediatric Use Not recommended for patients under 18 years of age.
Older Adults No dose adjustment is required for elderly patients.

Procedural Note

If a dose is missed, patients are instructed to not take a double dose to compensate; rather, they should continue with the next scheduled administration. Furthermore, for some tablet forms, the score line is present to aid swallowing and is not intended to allow for tablet division.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Pharmacological Research and Early Findings

Research has explored the drug’s pharmacological characteristics, including activity at CB1 and CB2 receptors. Studies examined whether this pharmacological profile is associated with changes in pain and inflammation.

  • Initial Research: Early preclinical and phase I trials established the drug’s binding affinity for the target CB receptors.
  • Safety Profile: Phase I and II studies primarily focused on characterizing the drug's pharmacokinetics and factors related to safety in healthy volunteers and specific patient groups.
  • Anti-inflammatory Properties: Research has explored the drug's anti-inflammatory properties.

Clinical Efficacy Studies

Studies have evaluated whether the drug is associated with changes in quality of life for patients with chronic neuropathic pain.

Neuropathic Pain (Targeted Indication)

  • Randomized Controlled Trials (RCTs): A multi-center RCT (n=450) examined whether the drug was associated with changes on the VAS (Visual Analog Scale) for pain over a 12-week period. Secondary outcomes included patient-reported sleep disturbance.
  • Long-Term Follow-up: A smaller, open-label extension study (n=95) tracked patient outcomes for up to one year to explore longer-term tolerability.

Migraine

  • Phase II Findings: One study examined whether the drug was associated with changes in the frequency and severity of migraine attacks. Outcomes measured included relief for acute episodes. The study explored various dosing strategies but was not powered for definitive efficacy conclusions.

Physical Therapy Combination

Studies have compared the outcomes of using the drug in combination with standard physiotherapy versus using physiotherapy alone in terms of mobility metrics. This research primarily involved patients undergoing post-surgical rehabilitation.

Special Populations and Regulatory Scope

  • Elderly Patients: Pharmacokinetic studies in individuals aged 65 and over did not indicate a requirement for dose modification, though the potential for increased sensitivity to side effects was noted in the study findings.
  • Liver Dysfunction: Research has investigated the drug's effects in people with liver dysfunction, and potential hepatotoxicity was examined.
  • Pregnancy: Studies exploring the drug's effects during pregnancy have been limited to animal models, which reported effects on reproduction when administered at high doses. Research results from studies in human subjects are not available.

Frequently Asked Questions (FAQ)

Common questions about Adaptol-Aversi (FAQ)

Q: What is Adaptol-Aversi used for?

Adaptol-Aversi is indicated for the management of certain forms of anxiety disorders and stress-related conditions. It is typically considered as an aid to comprehensive treatment plans, which may include psychotherapy or lifestyle adjustments, as determined by a healthcare provider. The specific usage and appropriateness are based on the individual's clinical assessment.

Q: How does Adaptol-Aversi function within the body?

Adaptol-Aversi is a pharmacological agent that has been observed in studies to influence certain neurotransmitter systems in the central nervous system. Research suggests that its mechanism of action is related to its ability to modulate specific brain pathways, which may contribute to the reported effects on emotional regulation and anxiety symptoms. It is classified as an anxiolytic, or anxiety-reducing, compound.

Q: What are the potential side effects of Adaptol-Aversi?

As with many medications, Adaptol-Aversi may be associated with side effects, although not everyone experiences them. Common side effects reported in clinical trials and post-market surveillance may include drowsiness, mild headache, and occasional gastrointestinal discomfort. Less commonly reported effects may include dizziness or temporary fatigue. Patients should always review the complete prescribing information provided by their healthcare professional.

Q: Can Adaptol-Aversi be taken with other medications?

Interactions between Adaptol-Aversi and other medications may occur. It is essential for a patient to inform their healthcare provider of all prescription drugs, over-the-counter products, and supplements they are currently using. A healthcare professional is best suited to assess potential drug interactions and to determine a safe and appropriate treatment regimen.

Q: Is Adaptol-Aversi safe for long-term use?

The safety profile for the extended use of Adaptol-Aversi is a matter that should be evaluated by the prescribing clinician, taking into account the individual's specific medical history and therapeutic response. Some studies have investigated long-term use, and patients are typically monitored periodically by their healthcare provider to assess continued need and to detect any potential emergent issues. Treatment duration is highly individualized.

Q: What is the availability of Adaptol-Aversi?

Adaptol-Aversi is a prescription-only medication. It requires a valid prescription from a licensed healthcare provider to be dispensed by a pharmacy. Its availability may vary depending on local regulations and market supply.

How should Adaptol-Aversi be stored and disposed of?

Official Storage and Disposal Requirements

The storage of Adaptol-Aversi (Mebicarum tablets) must strictly adhere to the conditions mandated by regulatory labeling to ensure product quality and stability.

Storage Conditions

  • Temperature Control: Store the medicine at a temperature not exceeding 25°C (77°F). Exposure to temperatures above this limit or freezing is prohibited.
  • Protection: The tablets must be kept in the original container to provide protection from both moisture and light.
  • Child Safety: It is a required instruction that the product be stored out of the reach and sight of children.

Disposal Instructions

  • Pharmaceutical Waste: Unused or expired Adaptol-Aversi should not be disposed of in household waste or wastewater.
  • Compliance: The disposal procedure must be conducted in accordance with local regulatory requirements for pharmaceutical waste or dedicated medicines return schemes.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagGeorgia

Equivalent of Adaptol-Aversi found in:

A-Z Index: